{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=23",
    "query": {
      "intervention": "Formulation #2",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1742,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T18:44:54.964Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03721107",
      "title": "A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Blautix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "4D pharma plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 366,
      "start_date": "2018-10-11",
      "completion_date": "2020-05-13",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03721107"
    },
    {
      "nct_id": "NCT01484964",
      "title": "A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of ASP015K",
        "Bioavailability of ASP015K",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-09",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484964"
    },
    {
      "nct_id": "NCT00725985",
      "title": "Oral Cladribine in Early Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rebif® new formulation (RNF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 617,
      "start_date": "2008-12-31",
      "completion_date": "2012-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00725985"
    },
    {
      "nct_id": "NCT04122755",
      "title": "Single Ascending Dose Study of ALA-1000",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "ALA-1000",
          "type": "DRUG"
        },
        {
          "name": "buprenorphine sublingual film",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alar Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2019-09-16",
      "completion_date": "2021-05-03",
      "has_results": false,
      "last_update_posted_date": "2021-12-30",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04122755"
    },
    {
      "nct_id": "NCT02792699",
      "title": "Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "ABP 798",
          "type": "DRUG"
        },
        {
          "name": "Rituximab (US)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab (EU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 311,
      "start_date": "2016-05-17",
      "completion_date": "2018-10-08",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 27,
      "location_summary": "Tuscaloosa, Alabama • Los Angeles, California • Thousand Oaks, California + 24 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792699"
    },
    {
      "nct_id": "NCT04903093",
      "title": "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Abrocitinib tablet",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F1",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F2",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F3",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F4",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F5",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F6",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2021-06-04",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903093"
    },
    {
      "nct_id": "NCT02779829",
      "title": "18432-Sun Protection Factor Assay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreening Agent"
      ],
      "interventions": [
        {
          "name": "Coppertone (BAY 987517)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2015-07-29",
      "completion_date": "2015-09-01",
      "has_results": false,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 1,
      "location_summary": "Union, New Jersey",
      "locations": [
        {
          "city": "Union",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779829"
    },
    {
      "nct_id": "NCT03416530",
      "title": "ONC201 in Pediatric H3 K27M Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "Dordaviprone (ONC201)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 134,
      "start_date": "2018-01-25",
      "completion_date": "2023-05-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03416530"
    },
    {
      "nct_id": "NCT05889273",
      "title": "ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "ML-004 (IR)/(ER) tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "46 Years",
        "sex": "ALL",
        "summary": "12 Years to 46 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-06-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 18,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05889273"
    },
    {
      "nct_id": "NCT06109441",
      "title": "Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "ALTB-268",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AltruBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-12-04",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-01T18:44:54.964Z",
      "location_count": 23,
      "location_summary": "San Diego, California • Littleton, Colorado • Miami, Florida + 20 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06109441"
    }
  ]
}